14th December 2022
BCI’s Dr Ana Rio-Machin is part of a new research collaboration agreement that will leverage Envisagenics’ SpliceCore® AI platform for expanded discovery and research in haematopoietic cancers.
Read more12th October 2021
Professors Claude Chelala and Louise Jones from Barts Cancer Institute, Queen Mary University of London, are part of a €21.3 million public-private research programme that will seek to use artificial intelligence to improve care for patients with prostate, breast and lung cancer.
Read more19th July 2021
We spoke with Group Leader Dr Jun Wang and Postdoctoral Researcher Dr Anthony Anene from Barts Cancer Institute’s Centre for Cancer Genomics & Computational Biology about their most recent publication. Published in Patterns, the paper describes the development of a machine-learning tool called ACSNI that can be used to predict tissue-specific pathway components from large biological datasets.
Read more8th February 2021
Researchers from Barts Cancer Institute, Queen Mary University of London, have released a web-based tool called SNPnexus COVID to streamline the analysis of host genetic sequencing data and allow for the identification and prioritisation of genetic variants that may impact an individual’s susceptibility to and the severity of COVID-19 infection.
Read more9th September 2020
A new study has identified molecular characteristics in ‘normal-looking’ tissues surrounding breast tumours that may indicate whether breast cancer is likely to return following surgical removal of the tumour.
Read more29th April 2019
April is Bowel Cancer Awareness Month. We recently spoke with Dr Kit Curtius about her work which focuses on understanding how normal tissues evolve to become cancerous, with a particular interest in gastrointestinal pre-malignancies such as inflammatory bowel disease.
Read more